FULC Q2 2019 Earnings — Fulcrum Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FULCFulcrum Therapeutics, Inc.

$411M

Q2 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$11M

Operating Income

-$13M

Net Income

-$13M

EPS (Diluted)

$-0.56

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$12M

Free Cash Flow

-$12M

Stock-Based Comp.

$950,000

Balance Sheet

Total Assets

$65M

Total Liabilities

$12M

Stockholders' Equity

$53M

Cash & Equivalents

$50M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$11M	$0	—
Operating Income	-$13M	-$8M	-71.9%
Net Income	-$13M	-$8M	-67.8%